Croissy-Beaubourg, September 30, 2022, 5:35 p.m. CEST – THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in vitro diagnostics and theranostics, announces the appointment of Crowe HAF by the Board of Directors of the Company in as an independent expert in the context of the proposed voluntary takeover bid filed by Biosynex.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]